Status:
COMPLETED
Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
Lead Sponsor:
VSM Geneesmiddelen b.v.
Conditions:
Raynaud Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.
Detailed Description
Despite more than 150 years of research into the pathophysiology of Raynaud´s phenomenon it is still not understood sufficiently. Three mean mechanisms responsible for Raynaud´s phenomenon are discuss...
Eligibility Criteria
Inclusion
- Primary Raynaud´s phenomenon
- History of episodic digital or toe pallor
- Duration of Raynaud´s phenomenon at least 2 years
- Suffering form regular occuring attacks prior to enrolment
Exclusion
- Secondary Raynaud´s phenomenon
- Connective tissue disease
- Large vessel disease
- Cryoglobulinemia, cold agglutinins disease, thrombocytosis
- Concomitant pharmacological treatment with effects on the vasculature
- Pregnancy or lactation
- Severe internal or systemic disease
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00251238
Start Date
November 1 2005
End Date
April 1 2006
Last Update
May 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMC ST Radboud
Nijmegen, Gelderland, Netherlands, 6525 GH